HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 49, Issue 1, 2009, Pages 93-98

  Yi, Xiaofang ^a,c   Zhou, Yi ^a   Zheng, Wenxin ^b   Chambers, Setsuko K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

Histological grade; HuR antigen; Ovarian neoplasms

Indexed keywords

HUR PROTEIN; ELAV-LIKE PROTEIN 1; MEMBRANE ANTIGEN; RNA BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL COUNT; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY;

ANTIGENS, SURFACE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RNA-BINDING PROTEINS;

EID: 66549086896     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2008.00937.x     Document Type: Article

References (21)

1. Fan XC, Steitz JA. Overexpression of Hu R, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 1998; 17: 3448-3460.
2. Nabors LB, Furneaux HM, King PH. Hu R, A novel target of anti-Hu antibodies, is expressed in non-neural tissues. J Neuroimmunol 1998; 92: 152-159.
3. Moore MJ, Nuclear RNA turnover. Cell 2002; 108: 431-434.
4. Erkinheimo TL, Lassus H, Sivula A et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase expression in serous ovarian carcinoma. Cancer Res 2003; 63: 7591-7594.
5. Denkert C, Weichert W, Pest S et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004; 64: 189-195.
6. Woo HH, Zhou Y, Yi X, et al. Regulation of non AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene 2009; doi: 10.1038/onc.2008.469 [ePub ahead of print].
7. Chambers SK, Ivins CM, Carcangiu ML. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF-1. Int J Cancer 1997; 74: 571-575.
8. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: A poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997; 3: 999-1007.
9. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79: 449-454.
10. Chambers SK, Ivins CM, Carcangiu ML. Urokinase-type plasminogen activator in epithelial ovarian cancer: A poor prognostic factor, associated with advanced stage. Int J Gynecol Cancer 1998; 8: 242-250.
11. Heinonen M, Bono P, Narko K et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005; 65: 2157-2161.
12. Fadare O, Reddy H, Wang J, Hileeto D, Schwartz PE, Zheng W. E-Cadherin and beta-catenin expression in early stage cervical carcinoma: A tissue microarray study of 147 cases. World J Surg Oncol 2005; 3: 38.
13. Denkert C, Weichert W, Winzer KJ et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004; 10: 5580-5586.
14. Denkert C, Koch I, von Keyserlingk N et al. Expression of the ELAV-like protein HuR in human colon cancer: Association with tumor stage and cyclooxygenase-2. Mod Pathol 2006; 19: 1261-1269.
15. López de Silanes I, Fan J, Yang X et al. Role of the RNAbinding protein HuR in colon carcinogenesis. Oncogene 2003; 22: 7146-7154.
16. Erkinheimo TL, Sivula A, Lassus H et al. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol 2005; 99: 14-19.
17. Nabors LB, Gillespie GY, Harkins L, King PH. Hu R, A RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001; 61: 2154-2161.
18. Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeyer TJ, Malkinson AM, Port JD. Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue. Mol Carcinog 2000; 28: 76-83.
19. Cherry J, Karschner V, Jones H, Pekala PH. Hu R, An RNA-binding protein, involved in the control of cellular differentiation. In Vivo 2006; 20: 17-23.
20. Lejbkowicz F, Goldberg-Cohen I, Levy AP. New horizons for VEGF. Is there a role for nuclear localization? Acta Histochem 2005; 106: 405-411.
21. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005.